NASDAQ:BMRNBioMarin Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $118.67 -0.98 (-0.82 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$117.81Now: $118.67▼$120.7550-Day Range$113.83MA: $124.31▼$131.0352-Week Range$62.88Now: $118.67▼$131.95Volume754,347 shsAverage Volume1.04 million shsMarket Capitalization$21.52 billionP/E Ratio179.80Dividend YieldN/ABeta1.05 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.74, and is based on 17 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $125.27, BioMarin Pharmaceutical has a potential upside of 5.6% from its current price of $118.67.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.1 Community Rank Outperform VotesBioMarin Pharmaceutical has received 1,446 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioMarin Pharmaceutical has received 868 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioMarin Pharmaceutical has received 62.49% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote “Outperform” if you believe BMRN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,606,515.00 in company stock.Percentage Held by InsidersOnly 2.15% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions96.68% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 209.80% in the coming year, from $0.51 to $1.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 179.80, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.38.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 179.80, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.47.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 6.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.67 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BMRN Previous Symbol CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone415-506-6700Debt Debt-to-Equity Ratio0.15 Current Ratio2.58 Quick Ratio1.72Price-To-Earnings Trailing P/E Ratio179.80 Forward P/E Ratio232.69 P/E GrowthN/A Sales & Book Value Annual Sales$1.70 billion Price / Sales12.63 Cash Flow$0.64 per share Price / Cash Flow186.25 Book Value$17.38 per share Price / Book6.83Profitability EPS (Most Recent Fiscal Year)$0.07 Net Income$-23,850,000.00 Net Margins6.62% Return on Equity4.40% Return on Assets2.98%Miscellaneous Employees3,001 Outstanding Shares181,350,000Market Cap$21.52 billion Next Earnings Date10/28/2020 (Estimated) OptionableOptionable $118.67 -0.98 (-0.82 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BMRN News and Ratings via Email Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions How has BioMarin Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)? BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BMRN shares have increased by 36.6% and is now trading at $118.67. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of BioMarin Pharmaceutical? 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 6 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioMarin Pharmaceutical. When is BioMarin Pharmaceutical's next earnings date? BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020. View our earnings forecast for BioMarin Pharmaceutical. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported $0.07 EPS for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.17. The biotechnology company earned $429.49 million during the quarter, compared to analyst estimates of $418.02 million. BioMarin Pharmaceutical had a net margin of 6.62% and a return on equity of 4.40%. View BioMarin Pharmaceutical's earnings history. What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.85-1.95 billion, compared to the consensus revenue estimate of $1.9 billion. What price target have analysts set for BMRN? 23 brokerages have issued 12-month price targets for BioMarin Pharmaceutical's shares. Their forecasts range from $77.00 to $156.00. On average, they expect BioMarin Pharmaceutical's stock price to reach $125.27 in the next year. This suggests a possible upside of 5.6% from the stock's current price. View analysts' price targets for BioMarin Pharmaceutical. Has BioMarin Pharmaceutical been receiving favorable news coverage? Media coverage about BMRN stock has been trending very negative on Sunday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a daily sentiment score of -3.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about BioMarin Pharmaceutical. Who are some of BioMarin Pharmaceutical's key competitors? Some companies that are related to BioMarin Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN). View all competitors. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (ARRY) and Freeport-McMoRan (FCX). Who are BioMarin Pharmaceutical's key executives? BioMarin Pharmaceutical's management team includes the following people: Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61) What is BioMarin Pharmaceutical's stock symbol? BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN." Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (4.20%), First Trust Advisors LP (0.63%), Manning & Napier Group LLC (0.54%), Frontier Capital Management Co. LLC (0.42%), Sumitomo Mitsui Trust Holdings Inc. (0.40%) and Swiss National Bank (0.39%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere. View institutional ownership trends for BioMarin Pharmaceutical. Which institutional investors are selling BioMarin Pharmaceutical stock? BMRN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Jennison Associates LLC, Frontier Capital Management Co. LLC, Manning & Napier Group LLC, TCW Group Inc., Great Lakes Advisors LLC, Scout Investments Inc., and Oregon Public Employees Retirement Fund. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, V Bryan Lawlis, and Willard H Dere. View insider buying and selling activity for BioMarin Pharmaceutical. Which institutional investors are buying BioMarin Pharmaceutical stock? BMRN stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Strs Ohio, Mckinley Capital Management LLC Delaware, State of Alaska Department of Revenue, Robeco Institutional Asset Management B.V., Janney Montgomery Scott LLC, State Board of Administration of Florida Retirement System, and WINTON GROUP Ltd. View insider buying and selling activity for BioMarin Pharmaceutical. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BioMarin Pharmaceutical's stock price today? One share of BMRN stock can currently be purchased for approximately $118.67. How big of a company is BioMarin Pharmaceutical? BioMarin Pharmaceutical has a market capitalization of $21.52 billion and generates $1.70 billion in revenue each year. The biotechnology company earns $-23,850,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. BioMarin Pharmaceutical employs 3,001 workers across the globe. What is BioMarin Pharmaceutical's official website? The official website for BioMarin Pharmaceutical is www.bmrn.com. How can I contact BioMarin Pharmaceutical? BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected] This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
